Codexis, Inc. (CDXS) News

Codexis, Inc. (CDXS): $2.94

0.13 (+4.63%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add CDXS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#192 of 347

in industry

Filter CDXS News Items

CDXS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CDXS News Highlights

  • CDXS's 30 day story count now stands at 6.
  • Over the past 16 days, the trend for CDXS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DEC, RNA and ECO are the most mentioned tickers in articles about CDXS.

Latest CDXS News From Around the Web

Below are the latest news stories about CODEXIS INC that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insu

Yahoo | December 27, 2023

Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company

Codexis, Inc. ( NASDAQ:CDXS ) shares have continued their recent momentum with a 41% gain in the last month alone...

Yahoo | December 18, 2023

Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?

Codexis, Inc. ( NASDAQ:CDXS ), might not be a large cap stock, but it received a lot of attention from a substantial...

Yahoo | December 15, 2023

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Deal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymesREDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global excl

Yahoo | December 13, 2023

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology. This critical technical milestone demonstrates the preparative-scale manufacture o

Yahoo | December 13, 2023

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8, 2023, to discuss the growth of RNA interference (RNAi) therapeutics as a modality, the manufacturing landscape and the potential role for the Company’s Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform to enable commercial-scale production of RNAi therapeutics. KOL participants included John Mar

Yahoo | December 11, 2023

Codexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 92% Above Its Share Price

Key Insights The projected fair value for Codexis is US$4.65 based on 2 Stage Free Cash Flow to Equity Codexis is...

Yahoo | November 30, 2023

3 Synthetic Biology Stocks Likely to Mint New Millionaires

Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.

Alex Sirois on InvestorPlace | November 29, 2023

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA interference (RNAi) therapeutics manufacturing landscape on Friday, December 8, 2023, at 10:00 am ET. The event will feature John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuti

Yahoo | November 28, 2023

Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023, in New York, New York. Management will participate in a fireside chat on Tuesday, November 28, 2023, at 9:30 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A re

Yahoo | November 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!